Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NeuroPace IncNPCE · Entity 5459 | Director | April 21, 2021 | October 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NeuroPace Inc
Report date April 21, 2021 · Filed October 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-04-20 | Direct | 21,698 |
Reported balance
After 2021-04-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-21 · Grant · Acquired 21,698 · Balance 21,698 F1: 1/36th of the shares subject to the option vest in equal monthly installments commencing May 21, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/36th of the shares subject to the option vest in equal monthly installments commencing May 21, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2021 Filed Apr 26, 2021 21:18 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionSeries B' Preferred Stock · Derivative | 3,454,422 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028329 · doc4.xml · derivative · entry 2 Norton Evan · CIK 0001856303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 3,454,422 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. F2 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. F1 · ownership.nature: Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Mr. Norton, a member of our board of directors, is a General Partner at Accelmed LLC. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:18 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionCommon Stock | 3,454,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028329 · doc4.xml · nonDerivative · entry 1 Norton Evan · CIK 0001856303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,042,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Mr. Norton, a member of our board of directors, is a General Partner at Accelmed LLC. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 23:26 UTC | NeuroPace Inc NPCE · Entity 5459 | PurchaseCommon Stock | 588,235 | $17.00 | $9,999,995.00 |
DisclosureSEC source: 0001209191-21-028188 · doc4.xml · nonDerivative · entry 1 Norton Evan · CIK 0001856303 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 588,235 F1 · shares: Reflects shares purchased from the underwriters in the Companys initial public offering. F2 · ownership.nature: Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Mr. Norton, a member of our board of directors, is a General Partner at Accelmed LLC. The address of each of Accelmed LLC, Accelmed Partners II GP, LP, Accelmed Partners II LP and Mr. Norton is Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands. Read SEC document |
| April 21, 2021 Filed Oct 8, 2021 22:17 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 21,698 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060106 · doc4.xml · derivative · entry 1 Norton Evan · CIK 0001856303 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,698 Underlying: Common Stock · 21,698 shares Expires 2031-04-20 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest in equal monthly installments commencing May 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.